Skip to content

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04022616
Enrollment
99
Registered
2019-07-17
Start date
2010-06-04
Completion date
2027-12-31
Last updated
2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Interventions

OTHERSpecimen collection

Specimens are obtained from patients who are being treated for breast malignancies.

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older * Ability to give informed consent * Stage I-III breast malignancy

Exclusion criteria

* Unable to tolerate venipuncture

Design outcomes

Primary

MeasureTime frameDescription
Isolate unfavorable immune cells MDSC from the peripheral blood or tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells.up to 1 yearFunction of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies. isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood or the tumors of study subjects and test how strongly they inhibit function of favorable immune cells called Natural Killer Cells. Function of Natural Killer Cells will be studied by measuring their ability to kill target cancer cells coated with monoclonal antibodies.

Secondary

MeasureTime frameDescription
Isolate unfavorable immune cells called Myeloid Derived Suppressor Cells (MDSC) from the peripheral blood of study subjects who plan to start pre-operative chemotherapy for breast cancer to see if MDSC levels can predict who will respond to treatment. Wup to 1 yearPercentage of MDSC at baseline and whether there is an association of baseline MDSC percent with response to chemotherapy.
Isolate unfavorable immune cells MDSC from peripheral blood of study subjects who receive pre-operative chemotherapy for breast cancer to identify changes in MDSC levels during treatment can predict who will respond to treatment.up to 1 yearChanges will be reported in percentage of MDSC and associations of such changes with response to chemotherapy.
Isolate lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present.up to 1 yearIsolate a lymph nodes from patients with breast cancer undergoing breast surgery to study what types of Natural Killer Cells are present. Natural Killer cells are immune cells that are capable of killing cancer cells.

Countries

United States

Contacts

CONTACTOhio State Comprehensive Cancer Center
OSUCCCClinicaltrials@osumc.edu1-800-293-5066
PRINCIPAL_INVESTIGATORWilliam Carson, MD

Ohio State Comprehensive Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026